AKUS

Akouos, Inc. [AKUS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

AKUS Stock Summary

In the News

AKUS Financial details

Company Rating
-
Market Cap
0
Income
-93.37M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
103
Optionable
No
Shortable
Yes
Earnings
15 Nov 2022
P/E
-7.17
Forward P/E
-
PEG
15.28
P/S
-
P/B
2.71
P/C
-
P/FCF
-
Quick Ratio
16.79
Current Ratio
17.3
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.64
EPS next Y
-
EPS next Q
-
EPS this Y
78.34%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-5.17%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-30%
ROE
-35%
ROC
-0.31%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.315-13.6
52W High
-
52W Low
-
RSI
-
Rel Volume
2.47
Avg Volume
725.97K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-0.561325
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
NVDA
3V64.DE
META
V
APC.DE
Same Sector
000227.KS
REPCF
234080.KS
GBIO
0690.HK
Check Those
SHSCX
FGNA
FTPAU
THL.NZ
BRISA.IS
Similar Market Cap
VLRS
INPSX
HWM
0KBL.L
GMAT3.SA

Company Profile

Healthcare Biotechnology
  • Volume Average 725.97K
  • Employee 103
  • CEO Dr. Emmanuel Simons M.B.A., Ph.D.
  • Headquarters Boston,MA,US
  • IPO Date 2020-06-26
  • Website https://www.akouos.com

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.